RTP Mobile Logo

Thursday, January 25, 2018, San Francisco, California, 6:45 PM – 8:45 PM (Pacific Time)

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer

Event Details

Location:
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Time:
6:30 PM – 6:45 PM (Pacific Time) — Registration

6:45 PM – 8:45 PM (Pacific Time) — Educational Dinner Meeting

Meeting Room:
Yerba Buena Ballroom, Salon 10-15 (Lower B2 Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Faculty:
Matthew D Hellmann, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

David R Spigel, MD
Program Director, Lung Cancer Research 
Sarah Cannon Research Institute
Nashville, Tennessee

Additional faculty to be announced

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.

Agenda

6:30 PM – 6:45 PM (Pacific Time) — Registration

6:45 PM – 8:45 PM (Pacific Time) — Educational Dinner Meeting

Overview
For this CME symposium, 4 lung cancer investigators with a specialized interest in immunotherapy will serve as the faculty, and RTP president and medical oncologist Dr Neil Love will serve as the moderator. Prior to the event, the faculty and 3 other investigators will complete a survey to provide their perspectives on a number of controversial questions and challenging clinical scenarios regarding the role of immune checkpoint inhibitors in the treatment of lung cancer. The responses from all 7 experts will be summarized and graphically presented to illustrate the group’s collective perspectives. The agenda will be divided into 4 distinct topic modules. Each of the four modules will feature moderated discussion surrounding the faculty members’ responses to an array of survey questions followed by a short, faculty member-led presentation reviewing recent data and ongoing research related to the scenarios in question.

Detailed agenda to be announced by mid-December.

Topics for Discussion

MODULE 1: Emerging Research Data with and Potential Clinical Role of Immune Checkpoint Inhibitors in the Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

MODULE 2: Integration of Anti-PD-1/PD-L1 Antibodies into Current Treatment Algorithms for Metastatic NSCLC

MODULE 3: Evaluation of Existing and Emerging Immunotherapeutic Approaches, Including Combination Strategies in NSCLC and Small Cell Lung Cancer (SCLC)

MODULE 4: Identification and Management of Immune-Mediated and Other Toxicities Associated with Checkpoint Inhibitors; Relative Contraindications for Patients with Existing Autoimmune Disease

CE Information

Target Audience:
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Compare and contrast the mechanisms of action, efficacy and safety/toxicity of approved and investigational anti-PD-1/PD-L1 antibodies for the treatment of non-small cell lung cancer (NSCLC) to determine the current and/or potential utility of each in clinical practice.
  • Review published research data documenting the safety and efficacy of anti-PD-1 antibodies as monotherapy or in combination with chemotherapy for newly diagnosed metastatic NSCLC.
  • Appraise emerging research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with unresectable Stage III NSCLC that has not progressed after standard platinum-based chemotherapy concurrent with radiation therapy.
  • Recognize immune-related adverse events and other common side effects associated with approved and developmental immune checkpoint inhibitors, and offer supportive management strategies to minimize and/or manage these toxicities.
  • Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches alone or in combination with other systemic therapies for NSCLC, and counsel appropriate patients about availability and participation.
  • Describe the biologic rationale and eligibility criteria for late-stage clinical trials evaluating novel applications of immune checkpoint inhibitors alone or in combination with other approaches (eg, anti-PD-1/PD-L1 antibodies in combination with other checkpoint inhibitors, radiation therapy, et cetera) for small cell lung cancer, and, where applicable, refer eligible patients for participation or other expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporter:
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Location

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room:
Yerba Buena Ballroom, Salon 10-15 (Lower B2 Level)

The San Francisco Marriott Marquis is the host hotel for the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.

 

Registration

This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME/CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.